


FIG. 1A




FIG. 1B




FIG. 1C



Stratum 1
Stratum 2
Group
All
iNOS
All
iNOS+
N
33
28
16
16
0%
-10%
-20%
-30%
-40%
-50%
-60%
-70%
-80%
Mean Change
*
†
*

FIG. 2




FIG. 3A



relative ROS levels
1.00
0.75
0.50
0.25
0.00
*
*
*
0
10
30
100
300
DPI
nmol/L CDDO-IM (24 hrs)

FIG. 3B




FIG. 3C



relative NO levels
(AFU (DAF2)
3.5
3.0
2.5
2.0
1.5
1.0
0.5
0.0
*
-
+
-
+
+ L-NAME
DMSO
CDDO-IM
PMA

FIG. 3D



Relative Optical Density
(Normalized to Loading Control)
1.0
0.8
0.6
0.4
0.2
0.0
Control
CRF
CRF + RTA dh404
**
††
***
†
**
ETA
ETB

FIG. 4




FIG. 5A



1.5
1.0
0.5
0.0
Densitometry
(Fold Vehicle Control)
Vehicle
BARD (30 mg/kg/day)
Recovery
**
Medulla
Cortex

FIG. 5B



Mean eGFR ± SE (ml/min/1.73 m²)
35.0
30.0
25.0
20.0
15.0
PBO
BARD
0
8
16
24
32
40
48
Week

FIG. 6



70%
60%
50%
40%
30%
20%
10%
0%
Percentage of Patients
PBO
ΔeGFR < -3
ΔeGFR < -5
ΔeGFR < -7.5
67%
37%
16%
0
8
16
24
32
40
48
Treatment Week
Number of PBO Patients with Data
1093
1023
885
726
547
402
281

FIG. 7A



70%
60%
50%
40%
30%
20%
10%
0%
Percentage of Patients
BARD
ΔeGFR < -3
ΔeGFR < -5
ΔeGFR < -7.5
20%
14%
8%
0
8
16
24
32
40
48
Treatment Week
Number of BARD Patients with Data
1092
958
795
628
461
345
241

FIG. 7B



Estimated Proportion of Patients with ESRD or CV Death by SDT
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64
Weeks Since Randomization
No. at risk (ITT Population)
BARD 1088 1077 1050 982 904 756 571 429 297 137 16
PBO 1097 1095 1076 1004 922 768 596 439 318 142 19

FIG.8



Estimated Proportion of Patients Hospitalized/Died of HF by SDT
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64
Weeks Since Randomization
No. at risk (ITT Population)
BARD 1088 1045 1006 942 864 723 548 417 288 133 15
PBO 1097 1089 1070 994 907 762 591 436 315 135 20

FIG.9



Estimated proportion of patients who died
0.25
0.20
0.15
0.10
0.05
0.00
0 4 8 12 16 24 32 40 48 56 64 72
Weeks Since Randomization
No. at risk (ITT Population)
BARD 1088 1082 1055 993 917 770 590 451 315 144 19 1
Placebo 1097 1096 1081 1010 930 786 624 464 341 156 23 0

FIG.10



Mean Serum Magnesium (mEq/L)
1.80
1.75
1.70
1.65
1.60
1.55
1.50
1.45
0
8
16
24
32
40
48
Weeks
Placebo
Bardoxolone Methyl

FIG. 11



Mean SBP Change ± SE (mmHg)
8.0
4.0
0.0
-4.0
-8.0
PBO
BARD
0
4
8
12
16
24
32
40
48
Treatment Week

FIG. 12A



Mean DBP Change ± SE (mmHg)
5.0
3.0
1.0
-1.0
-3.0
-5.0
PBO
BARD
0
4
8
12
16
24
32
40
48
Treatment Week

FIG. 12B



ABPM WK4 Mean SBP
Change ± SE (mmHg)
8.0
4.0
0.0
-4.0
-8.0
PBO (n = 71)
BARD (n = 66)
All
Day
Night

FIG. 13A



ABPM WK4 Mean DBP
Change ± SE (mmHg)
5.0
3.0
1.0
-1.0
-3.0
-5.0
PBO (n = 71)
BARD (n = 66)
All
Day
Night

FIG. 13B



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
20 mg BARD
90% CI

FIG.14A



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
20 mg BARD
90% CI

FIG.14B



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
80 mg BARD
90% CI

FIG.14C



ΔΔ Systolic Blood Pressure (mmHg)
10
8
6
4
2
0
−2
−4
−6
−8
−10
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)
80 mg BARD
90% CI

FIG.14D



20 mg BM
90% CI
ΔΔ QTcF (ms)
20
15
10
5
0
−5
−10
−15
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)

FIG.15A



80 mg BM
90% CI
ΔΔ QTcF (ms)
20
15
10
5
0
−5
−10
−15
0
2
4
6
8
10
12
14
16
18
20
22
24
Time (h)

FIG. 15B



1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Survival Estimate
1st
Month
Avasentan 25 mg
Avasentan 50 mg
Placebo
ASCEND
0
1
2
3
4
5
6
Time (Months)
Patients at risk (n)
25mg 455 206 141 106
50mg 478 213 130 96
Placebo 459 309 211 152

FIG.16A




FIG. 16B



r^2=0.22, p<0.001
Plasma ET-1 (pg/m)
12
10
8
6
4
2
0
0
30
60
90
120
150
180
eGFR (ml/min/1.73 m^2)

FIG.17A



r^2=0.47, p<0.001
FeET-1 (%)
15
12
9
6
3
0
0
30
60
90
120
150
180
eGFR (ml/min/1.73 m^2)

FIG.17B



Histology Scores
7
6
5
4
3
2
1
0
Vehicle
RTA dh404 (2 mg/kg)
RTA dh404 10 mg/kg)
RTA dh404 (30 mg/kg)
Sildenafil
Arteriolar Hypertrophy
Pulmonary Edema
Cell/Fibrin Infiltrate
Summed Score

FIG. 18



mRNA Expression in Lung
(Fold Vehicle Control)
Vehicle
RTA dh404 (2 mg/kg)
RTA dh404 (10 mg/kg)
RTA dh404 (30 mg/kg)
Sidlenafil
0
1
2
3
4
Nqo1
Srxn1
Txnrd1
Gclc
Gclm
Gstp1
Gpx3
Cat

FIG. 19



mRNA Expression in Lung
(Fold Vehicle Control)
4
3
2
1
0
Vehicle
RTA dh404 (2 mg/kg)
RTA dh404 (10 mg/kg)
RTA dh404 (30 mg/kg)
Sidlenafil
Cox-2
iNos
IL-6
IL-10
Mip-2
Mcp-1

FIG. 20